Serap Annette Akgür
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Serap Annette Akgür has a total of 230 co-authors. Here are the top co-authors by number of shared publications:
- Melike Aydoğdu
Ege University Institute on Drug Abuse, Toxicology and Pharmaceutical Science, İzmir, Turkey
14 shared publications - Rukiye Aslan
Ege University Institute on Drug Abuse, Toxicology and Pharmaceutical Science, Izmir, Türkiye
13 shared publications - Duygu Yeşim Ovat
Institute on Drug Abuse, Toxicology and Pharmaceutical Science, Ege University
7 shared publications - Nebile Daglioglu
Department of Forensic Toxicology, Institute of Forensic Sciences, Ankara University, Ankara, Türkiye
5 shared publications Rukiye Döğer
5 shared publications- Alev Aktaş
Sivas Cumhuriyet Üniversitesi
4 shared publications
Latest Publications
- 5 June 2026
- Published by Academician Publishing
- p. 197-214
Parmak İzlerinin Kimyasal Analizlerinde Karşılaşılan Zorluklar
- 5 June 2026
- Published by Academician Publishing
- p. 197-214
Parmak İzlerinin Kimyasal Analizlerinde Karşılaşılan Zorluklar
- Open Access
- 5 June 2026
- Published by Academician Publishing
Parmak İzi Araştırmaları: Güncel Yaklaşımlar
- 5 June 2026
- Published by Academician Publishing
Open AccessParmak İzi Araştırmaları: Güncel Yaklaşımlar
- Open Access
- 17 April 2026
- Published by Elsevier in Journal of Chromatography Open
- Vol. 9
Overcoming fiber degradation: A green headspace solid-phase microextraction method with on-fiber derivatization for urinary amphetamines
- 17 April 2026
- Published by Elsevier in Journal of Chromatography Open
- Vol. 9
Open AccessOvercoming fiber degradation: A green headspace solid-phase microextraction method with on-fiber derivatization for urinary amphetamines
- Open Access
- 7 April 2026
- Published by Springer Nature in International journal of legal medicine
- Vol. 140 (4) , 2065-2078
Impact of CBD and hemp oil use on drug test results: a systematic review
Hemp-derived products, especially CBD (cannabidiol) oil and hemp oil, have shown a notable increase of use in recent years. CBD oil is a compound derived from the cannabis plant, whilst hemp oil is a product derived from hemp seeds. Trans-Δ9-tetrahydrocannabinol (THC) in cannabis is responsible for the psychoactive effect, whereas CBD, having the same molecular weight, is a non-psychoactive compound with analgesic, antiepileptic, antibacterial and anti-inflammatory effects. The rapid uptake of these products has raised concerns about unintended cannabinoid findings (THC, 11-OH-THC and THC-COOH etc.) on drug tests, especially in workplaces, road safety applications, and anti-doping programs. Although many CBD and hemp oils are marketed as “THC-free,” trace amounts of THC may be present in some products due to manufacturing variability, mislabeling, or contamination. These trace amounts may yield detectable levels in biological matrices or may cause cannabinoids findings. Regulatory frameworks for THC in cannabis products exist in several jurisdictions, but oversight of CBD-containing oils remains heterogeneous, creating gaps in quality control and labeling. This systematic review aimed to evaluate whether the use of CBD and hemp oil may lead to cannabinoid-positive results in drug testing, potentially causing suspicion of cannabis use. The research design was prepared according to the PRISMA guidelines. The review included studies published in English between March 2014 and March 2024 that met the search criteria based on the keywords “psychoactive effects”, “forensic toxicology”, “THC positive”, “delta-9-tetrahydrocannabinol”, “delta-9-THC”, “test”, and “analysis” paired with the terms “CBD Oil” and “Hemp Oil” separately in the PubMed, WOS, and SCOPUS databases. The literature search yielded 477 results, 12 of which met the inclusion criteria. Eight of the 12 studies included evaluate of the possibility of positive cannabinoid findings or negative results in biological materials as a result of CBD and hemp oil use in humans. Five of these studies reported that the use of these oils would not create a positive result above the “limit of detection (LOQ) or cut-off levels” in the drug tests for THC. Although concentrations above the limit were not encountered, it is noteworthy, that trace levels or those close to the detection limits of cannabinoid levels were obtained. There are four studies designed to evaluate the conversion of CBD to THC in human metabolism after the use of oil products and two out of four studies emphasize that there will be no biotransformation or extraction-induced transformation after the use of CBD and hemp oils. This systematic review addresses current evidence on the occurrence and underlying causes of cannabinoid-positive drug test results following the consumption of CBD and hemp oils, highlighting critical gaps in analytical testing strategies and regulatory oversight. Positivity mainly arises from the product content (e.g., undeclared or excessive THC, mislabeling, and contamination), the matrix, the administration route, and the sensitivity and specificity of the analytical methods. The potential for CBD to convert to THC during manufacturing or in the human body may pose legal risks for individuals using CBD or hemp oil in countries with zero-tolerance policies.
- 7 April 2026
- Published by Springer Nature in International journal of legal medicine
- Vol. 140 (4) , 2065-2078
Open AccessImpact of CBD and hemp oil use on drug test results: a systematic review
Hemp-derived products, especially CBD (cannabidiol) oil and hemp oil, have shown a notable increase of use in recent years. CBD oil is a compound derived from the cannabis plant, whilst hemp oil is a product derived from hemp seeds. Trans-Δ9-tetrahydrocannabinol (THC) in cannabis is responsible for the psychoactive effect, whereas CBD, having the same molecular weight, is a non-psychoactive compound with analgesic, antiepileptic, antibacterial and anti-inflammatory effects. The rapid uptake of these products has raised concerns about unintended cannabinoid findings (THC, 11-OH-THC and THC-COOH etc.) on drug tests, especially in workplaces, road safety applications, and anti-doping programs. Although many CBD and hemp oils are marketed as “THC-free,” trace amounts of THC may be present in some products due to manufacturing variability, mislabeling, or contamination. These trace amounts may yield detectable levels in biological matrices or may cause cannabinoids findings. Regulatory frameworks for THC in cannabis products exist in several jurisdictions, but oversight of CBD-containing oils remains heterogeneous, creating gaps in quality control and labeling. This systematic review aimed to evaluate whether the use of CBD and hemp oil may lead to cannabinoid-positive results in drug testing, potentially causing suspicion of cannabis use. The research design was prepared according to the PRISMA guidelines. The review included studies published in English between March 2014 and March 2024 that met the search criteria based on the keywords “psychoactive effects”, “forensic toxicology”, “THC positive”, “delta-9-tetrahydrocannabinol”, “delta-9-THC”, “test”, and “analysis” paired with the terms “CBD Oil” and “Hemp Oil” separately in the PubMed, WOS, and SCOPUS databases. The literature search yielded 477 results, 12 of which met the inclusion criteria. Eight of the 12 studies included evaluate of the possibility of positive cannabinoid findings or negative results in biological materials as a result of CBD and hemp oil use in humans. Five of these studies reported that the use of these oils would not create a positive result above the “limit of detection (LOQ) or cut-off levels” in the drug tests for THC. Although concentrations above the limit were not encountered, it is noteworthy, that trace levels or those close to the detection limits of cannabinoid levels were obtained. There are four studies designed to evaluate the conversion of CBD to THC in human metabolism after the use of oil products and two out of four studies emphasize that there will be no biotransformation or extraction-induced transformation after the use of CBD and hemp oils. This systematic review addresses current evidence on the occurrence and underlying causes of cannabinoid-positive drug test results following the consumption of CBD and hemp oils, highlighting critical gaps in analytical testing strategies and regulatory oversight. Positivity mainly arises from the product content (e.g., undeclared or excessive THC, mislabeling, and contamination), the matrix, the administration route, and the sensitivity and specificity of the analytical methods. The potential for CBD to convert to THC during manufacturing or in the human body may pose legal risks for individuals using CBD or hemp oil in countries with zero-tolerance policies.
- Open Access
- 31 December 2025
- Published by Academician Publishing in The Bulletin of Legal Medicine
- Vol. 30 (3) , 188-196
The impact of opiate cut-off values in urine samples: Evaluation of 8 years of data
Objective: Opiates are one of the most abused drugs with growing concern.In recent years, it is seen that changes have been made to the cut-off values for opiates.The cut-offs for opiates in screening tests increased from 300 to 2000ng/mL.The aim of this study was to present the opiate results of 8-year study and to evaluate the data according to cut-off values increased from 300 to 2000 ng/mL.Methods: A total of 11,348 urine samples were analyzed between 2014–2021.Preliminary diagnoses, outpatient admissions, and toxicological test results were compared under two cut-offs. Screening tests were performed using immunoassay method (Randox Evidence and CEDIA), and confirmation analysis was conducted by Gas Chromatography-Mass Spectrometry (GC-MS). Results: At the 300 ng/mL cut-off value, 3.45% of the cases were opiate-positive. 69.1% of the cases were from addiction clinics, demonstrating the clinical importance of sensitive cut-offs in detecting substance use among patients requiring treatment. In this study, it is shown that 39.8% of cases requiring judicial action were missed when the cut-off value was raised to 2000 ng/mL, highlighting the risk of false negatives in forensic settings.Conclusion: The findings highlight that opiate cut-off values and analytical sensitivity may influence both medical evaluations and legal interpretations.
- 31 December 2025
- Published by Academician Publishing in The Bulletin of Legal Medicine
- Vol. 30 (3) , 188-196
Open AccessThe impact of opiate cut-off values in urine samples: Evaluation of 8 years of data
Objective: Opiates are one of the most abused drugs with growing concern.In recent years, it is seen that changes have been made to the cut-off values for opiates.The cut-offs for opiates in screening tests increased from 300 to 2000ng/mL.The aim of this study was to present the opiate results of 8-year study and to evaluate the data according to cut-off values increased from 300 to 2000 ng/mL.Methods: A total of 11,348 urine samples were analyzed between 2014–2021.Preliminary diagnoses, outpatient admissions, and toxicological test results were compared under two cut-offs. Screening tests were performed using immunoassay method (Randox Evidence and CEDIA), and confirmation analysis was conducted by Gas Chromatography-Mass Spectrometry (GC-MS). Results: At the 300 ng/mL cut-off value, 3.45% of the cases were opiate-positive. 69.1% of the cases were from addiction clinics, demonstrating the clinical importance of sensitive cut-offs in detecting substance use among patients requiring treatment. In this study, it is shown that 39.8% of cases requiring judicial action were missed when the cut-off value was raised to 2000 ng/mL, highlighting the risk of false negatives in forensic settings.Conclusion: The findings highlight that opiate cut-off values and analytical sensitivity may influence both medical evaluations and legal interpretations.
- 31 August 2025
- Published by Erzincan Universitesi Fen Bilimleri Ensitusu Dergisi in Erzincan Üniversitesi Fen Bilimleri Enstitüsü Dergisi
- Vol. 18 (2) , 505-520
APTAMER-BASED ELECTROCHEMICAL SENSORS FOR ILLICIT DRUG DETECTION: FORENSIC APPLICATIONS IN THE LAST DECADE YEARS
Illicit drugs are a global problem, and a variety of selective techniques are urgently needed to detect drugs of interest. Biosensors are integrated devices that combine biological recognition elements with transducers. Aptasensors are aptamer-based affinity biosensors, which are known for their exceptional specificity and high binding affinity to target molecules, and are providing significant advancements in the field of health, food, environmental, and forensic applications. Many aptasensors are nearly identical to conventional immunochemical aptamer, and aptamers are analogous to antibodies. Electrochemical aptasensors are aptamer for biological recognition integrated with electrochemical transduction. Recent studies on the use of electrochemical aptasensors for the detection of illicit drugs, including cannabis, opioids and amphetamine derivatives, in the last decade are discussed in this section. This section aims to present current technologies and challenges, and highlights gaps in the literature that can be addressed. This review emphasises the need for further research and development to improve the sensitivity, selectivity and applicability of aptasensors for point-of-care applications.
- 31 August 2025
- Published by Erzincan Universitesi Fen Bilimleri Ensitusu Dergisi in Erzincan Üniversitesi Fen Bilimleri Enstitüsü Dergisi
- Vol. 18 (2) , 505-520
APTAMER-BASED ELECTROCHEMICAL SENSORS FOR ILLICIT DRUG DETECTION: FORENSIC APPLICATIONS IN THE LAST DECADE YEARS
Illicit drugs are a global problem, and a variety of selective techniques are urgently needed to detect drugs of interest. Biosensors are integrated devices that combine biological recognition elements with transducers. Aptasensors are aptamer-based affinity biosensors, which are known for their exceptional specificity and high binding affinity to target molecules, and are providing significant advancements in the field of health, food, environmental, and forensic applications. Many aptasensors are nearly identical to conventional immunochemical aptamer, and aptamers are analogous to antibodies. Electrochemical aptasensors are aptamer for biological recognition integrated with electrochemical transduction. Recent studies on the use of electrochemical aptasensors for the detection of illicit drugs, including cannabis, opioids and amphetamine derivatives, in the last decade are discussed in this section. This section aims to present current technologies and challenges, and highlights gaps in the literature that can be addressed. This review emphasises the need for further research and development to improve the sensitivity, selectivity and applicability of aptasensors for point-of-care applications.
- Open Access
- 31 March 2025
- Published by Ozel Bagimlilik Ltd. in Bağımlılık Dergisi
- Vol. 26 (1) , 133-136
Endüstriyel Amaçlı Kannabis Yetiştiriciliğinde Psikoaktif Etkili Kannabinoidlerden Kaynaklanan Sorunlar
Geçmişi çok eski tarihlere uzanan kannabis bitkisi son yüzyılda bağımlık yapmayan bir madde olarak tıbbi amaçlı olarak kullanılabileceği, ancak içerdiği psikoaktif kannabinoidler nedeniyle kontrol edilmesi gereken bir madde olarak yasal düzenlemelerde yer almaktadır. Doğal kannabinoidlerin psikoaktif etkilerinden asıl sorumlu olan Δ9-Tetrahidrokannabinol (Δ9-THC), kannabinoidlerin farmakokinetiğini anlamak için yapılan çalışmalarda da en çok araştırılan molekül olmuştur. Ancak çok yeni olarak başka kannabinoidlerin de psikoaktif etkilerinin olduğu çalışmalarla gösterilmektedir. Endüstriyel kenevir yetiştirenler, kenevirden Δ9-THC de çıkartabilmekte ve bu durum yasadışı alanlarda kullanıma fırsat verebilmektedir. Dünyada ve ülkemizde endüstriyel kenevir bitkisinin yetiştirilmesi özellikle diğer endüstri bitkilerine göre daha az maliyetle üretilebilmesi, soğuk iklim bölgelerinde bile yüksek biyokütle verimi üretebilmesi, yaşam döngüsü boyunca çevre dostu özellikler göstermesi, kullanım alanlarının daha fazla olması vb. nedeniyle önemli bir ivme kazanmıştır. 2023 yılında endüstriyel ve ilaç etkin maddesi üretmek için kenevir yetiştiriciliği ile ilgili yapılan yeni yasal düzenlemeler sonrasında bu konu daha da önem kazanmıştır. Ülkemizde yeniden ivme kazanan endüstriyel kenevir yetiştiriciliği sürecinde geliştirilen politikaların, bu alanda hazırlanacak yönetmeliklerin, adli toksikolojik analiz yöntemlerinin multisidipliner yaklaşımlarla yapılması amacıyla bu çalışma yapılmıştır.
- 31 March 2025
- Published by Ozel Bagimlilik Ltd. in Bağımlılık Dergisi
- Vol. 26 (1) , 133-136
Open AccessEndüstriyel Amaçlı Kannabis Yetiştiriciliğinde Psikoaktif Etkili Kannabinoidlerden Kaynaklanan Sorunlar
Geçmişi çok eski tarihlere uzanan kannabis bitkisi son yüzyılda bağımlık yapmayan bir madde olarak tıbbi amaçlı olarak kullanılabileceği, ancak içerdiği psikoaktif kannabinoidler nedeniyle kontrol edilmesi gereken bir madde olarak yasal düzenlemelerde yer almaktadır. Doğal kannabinoidlerin psikoaktif etkilerinden asıl sorumlu olan Δ9-Tetrahidrokannabinol (Δ9-THC), kannabinoidlerin farmakokinetiğini anlamak için yapılan çalışmalarda da en çok araştırılan molekül olmuştur. Ancak çok yeni olarak başka kannabinoidlerin de psikoaktif etkilerinin olduğu çalışmalarla gösterilmektedir. Endüstriyel kenevir yetiştirenler, kenevirden Δ9-THC de çıkartabilmekte ve bu durum yasadışı alanlarda kullanıma fırsat verebilmektedir. Dünyada ve ülkemizde endüstriyel kenevir bitkisinin yetiştirilmesi özellikle diğer endüstri bitkilerine göre daha az maliyetle üretilebilmesi, soğuk iklim bölgelerinde bile yüksek biyokütle verimi üretebilmesi, yaşam döngüsü boyunca çevre dostu özellikler göstermesi, kullanım alanlarının daha fazla olması vb. nedeniyle önemli bir ivme kazanmıştır. 2023 yılında endüstriyel ve ilaç etkin maddesi üretmek için kenevir yetiştiriciliği ile ilgili yapılan yeni yasal düzenlemeler sonrasında bu konu daha da önem kazanmıştır. Ülkemizde yeniden ivme kazanan endüstriyel kenevir yetiştiriciliği sürecinde geliştirilen politikaların, bu alanda hazırlanacak yönetmeliklerin, adli toksikolojik analiz yöntemlerinin multisidipliner yaklaşımlarla yapılması amacıyla bu çalışma yapılmıştır.
- Open Access
- 26 March 2025
- Published by Wiley in Journal of Forensic Sciences
- Vol. 70 (3) , 1125-1132
Abuse of gabapentinoids in individuals with substance use disorders
The abuse of gabapentinoids has increased rapidly, and death cases have been reported with increasing rates. This study examines the toxicological analysis data of substance abuse cases conducted after legal regulations were implemented in Türkiye. The focus will be on the medicolegal implications of gabapentinoid positivity in these cases. Urine samples collected between July 2021 and July 2022 from individuals (ages 18–45) presenting at Manisa Mental Health and Diseases Hospital with diagnosed or suspected substance use disorders were analyzed for the presence of pregabalin, gabapentin, and other accompanying substances. High‐resolution liquid chromatography‐mass spectrometry (Orbitrap) was employed for analysis. The analysis reports and sociodemographic data of 10,300 cases were retrieved from the patient record system and subjected to statistical analysis using SPSS 25.0. Gabapentinoid positivity was detected in 21.6% (n = 2224) of these cases (pregabalin (PGB) 18.9% (n = 1943) and gabapentin (GBP) 5.3% (n = 546)). Of the positive cases, 93.9% (n = 2089) were male, with an average age of 28 ± 6.7. Forensic cases (probation and judicial) represented the majority of admitted and positive cases 2.6% (n = 265) of cases tested positive for both pregabalin and gabapentin. While an overall increase in pregabalin and gabapentin positivity rates was observed over time, a statistically significant difference (p < 0.05) was noted between years. Seven substances were detected with gabapentinoids. Methamphetamine was the most common accompanying substance, representing nearly half of the detected substances (46.8%, n = 1040), followed by THC‐COOH (26.8%, n = 595). Despite legal regulations, the use of gabapentinoids is increasing rapidly. The study highlights the urgent need to include gabapentinoids in routine screening tests, enforce stricter prescribing guidelines, and actively prevent their illegal use.
- 26 March 2025
- Published by Wiley in Journal of Forensic Sciences
- Vol. 70 (3) , 1125-1132
Open AccessAbuse of gabapentinoids in individuals with substance use disorders
The abuse of gabapentinoids has increased rapidly, and death cases have been reported with increasing rates. This study examines the toxicological analysis data of substance abuse cases conducted after legal regulations were implemented in Türkiye. The focus will be on the medicolegal implications of gabapentinoid positivity in these cases. Urine samples collected between July 2021 and July 2022 from individuals (ages 18–45) presenting at Manisa Mental Health and Diseases Hospital with diagnosed or suspected substance use disorders were analyzed for the presence of pregabalin, gabapentin, and other accompanying substances. High‐resolution liquid chromatography‐mass spectrometry (Orbitrap) was employed for analysis. The analysis reports and sociodemographic data of 10,300 cases were retrieved from the patient record system and subjected to statistical analysis using SPSS 25.0. Gabapentinoid positivity was detected in 21.6% (n = 2224) of these cases (pregabalin (PGB) 18.9% (n = 1943) and gabapentin (GBP) 5.3% (n = 546)). Of the positive cases, 93.9% (n = 2089) were male, with an average age of 28 ± 6.7. Forensic cases (probation and judicial) represented the majority of admitted and positive cases 2.6% (n = 265) of cases tested positive for both pregabalin and gabapentin. While an overall increase in pregabalin and gabapentin positivity rates was observed over time, a statistically significant difference (p < 0.05) was noted between years. Seven substances were detected with gabapentinoids. Methamphetamine was the most common accompanying substance, representing nearly half of the detected substances (46.8%, n = 1040), followed by THC‐COOH (26.8%, n = 595). Despite legal regulations, the use of gabapentinoids is increasing rapidly. The study highlights the urgent need to include gabapentinoids in routine screening tests, enforce stricter prescribing guidelines, and actively prevent their illegal use.